SCHEMBL14749365

SCHEMBL14749365

O=C(Cc1cccc(C(F)(F)F)c1)N1CCCC(c2cc(-c3ccc(F)cc3)nn2-c2ncccn2)C1

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ PRCP P42785 5/20 0.60
▸ MEN1 O00255 1/20 0.49
▸ KMT2A Q03164 1/20 0.49
▸ KDM4E B2RXH2 3/20 0.44
▸ SYK P43405 2/20 0.43
▸ ALDH1A1 P00352 2/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ GPR142 Q7Z601 1/20 0.41
▸ GAA P10253 1/20 0.40
▸ MAP3K12 Q12852 1/20 0.40
▸ CNR1 P21554 1/20 0.39
▸ USP2 O75604 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ ALOX15 P16050 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14752561 0.92 PRCP (0.62) PRCPMEN1KMT2AKDM4ESYK
SCHEMBL14752663 0.89 PRCP (0.56) PRCPKDM4EALDH1A1SMN1; SMN2MAP3K12
SCHEMBL14749356 0.87 PRCP (0.54) PRCPKDM4ESYKALDH1A1SMN1; SMN2
SCHEMBL14749320 0.85 PRCP (0.58) PRCPKDM4ESYKALDH1A1SMN1; SMN2
SCHEMBL14749316 0.85 PRCP (0.57) PRCPKDM4EALDH1A1SMN1; SMN2GAA
SCHEMBL14749329 0.85 PRCP (0.59) PRCPMEN1KMT2AKDM4EALDH1A1
SCHEMBL14749328 0.85 PRCP (0.61) PRCPALDH1A1SMN1; SMN2MAP3K12
SCHEMBL12184064 0.85 PRCP (0.83) PRCPKDM4ESYKALDH1A1SMN1; SMN2
SCHEMBL14749319 0.84 PRCP (0.57) PRCPKMT2AKDM4EALDH1A1SMN1; SMN2
SCHEMBL12184104 0.83 PRCP (0.51) PRCPKDM4EALDH1A1SMN1; SMN2MAP3K12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130059830-A1 NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS MERCK SHARP & DOHME CORP 2013-03-07 — — US disclosed
US-20130059830-A1 NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS MERCK SHARP & DOHME CORP 2013-03-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130059830-A1 NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS PRCP, PREP, ENPEP PRCP 1/4885MEN1 3238/4885KMT2A 2172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback